Approved for Use in Europe to Identify Head and Neck Cancer Patients Most Likely to Benefit from Opdivo (nivolumab) Therapy SANTA CLARA, Calif., May 15, 2017 Agilent Technologies Inc. (NYSE: A) today announced the expanded use of Agilent’s Dako PD-L1 IHC 28-8 pharmDx test for squamous cell carcinoma of the head and neck (SCCHN), the... Read more
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher’s acquisition of Patheon. Thermo Fisher will commence a tender offer... Read more
May 12, 2017 MilliporeSigma Opens New M Lab™ Collaboration Center in Bangalore Customers can explore new technologies and solutions to address development and manufacturing challenges Simulates a GMP manufacturing environment to accelerate development of new therapies MilliporeSigma, a leading science and technology company, today announced the expansion of its M Lab™ Collaboration Center in Bangalore,... Read more
Download PDF Read more
11 May 2017 Microsaic Systems plc (“Microsaic”, “Microsaic Systems” or the “Company”) Microsaic enhances capabilities of its 4000 MiD® miniaturised mass spectrometer for bioprocessing applications Microsaic Systems plc (AIM: MSYS), the developer of chip-based mass spectrometry (MS) instruments, has developed a novel technology to enable real-time analysis of proteins in bioprocessing applications, such as in... Read more
Basel, 10 May 2017 Roche provides update on phase III study of TECENTRIQ® (atezolizumab) in people with previously treated advanced bladder cancer IMvigor211 study did not meet its primary endpoint of overall survival (OS) compared to chemotherapy The safety profile was consistent with what has been previously observed for TECENTRIQ Roche (SIX: RO, ROG; OTCQX:... Read more
Basel, 10 May 2017 Roche provides update on phase III study of TECENTRIQ® (atezolizumab) in people with previously treated advanced bladder cancer IMvigor211 study did not meet its primary endpoint of overall survival (OS) compared to chemotherapy The safety profile was consistent with what has been previously observed for TECENTRIQ Roche (SIX: RO, ROG; OTCQX:... Read more
Download PDF Read more
PLEASANTON, Calif., May 2, 2017 /PRNewswire/ — Unchained Labs, the life sciences company that’s all about getting biologics researchers the right tool for the job, launched their new Unfilter today. The proprietary, 96-well ultrafiltration consumable is designed for use on the company’s one-of-a-kind, fully automated buffer exchange systems Freeslate and Junior. Unfilter gives researchers complete... Read more